Invest Clin 60(4): 310 - 318, 2019 https://doi.org/10.22209/IC.v60n4a05
The effects of vitamin D supplementation on endogen amylin hormone, hormonal and biochemical parameters, and insulin resistance in type-2 diabetic patients with
vitamin D deficiency in the Kurdistan Region of Iraq.
Mudhafar Mohamed M. Saeed1, Abdulqader Azeez Al-Naqshabandi1 and Hawri Fatih Sami Aldawoodi2
1College of Pharmacy, Hawler Medical University, Erbil, Kurdistan region, Iraq. 2Department of Biology, College of Science,Cihan University, Erbil, Kurdistan region, Iraq.
Efectos de la suplementacion de Vitamina D sobre la hormona endógena amilina, parámetros hormonales y bioquímicos,
e insulina resistencia en pacientes diabéticos tipo 2 con deficiencia de Vitamina D en la región Kurdistan de Irak. Invest Clin 2019; 60 (4): 310-318
Received: 25-02-2019 Accepted 16-10-2019
A growing research evidence has con- cluded that type-2 diabetes (T2D) and its complications are significant causes of mor- bidity and mortality worldwide (1). As a crucial global health condition, 415 million people are afflicted with T2D, and it will in- crease to 642 million by 2040 (2). Vitamin D deficiency (a prohormone) is also consid- ered as a public health problem throughout the world (3). Vitamin D is an essential fat- soluble secostroid responsible for the main-
tenance of calcium homeostasis and good physical condition of the bone, and it has also been proved that this vitamin is associ- ated with hypertension, diabetes, metabolic syndrome, cancer, and autoimmune and in- fectious diseases (4). Observational studies have indicated that vitamin D deficiency is associated with the onset of T2D, its pro- gression, and subsequent macrovascular complications (5-9).
Amylin is a hormone composed of 37-amino acid peptides. It is synthesized and co-localized with insulin in the beta-cells of
pancreatic islets (10). Amylin is co-secreted with insulin from beta-cells of pancreatic islets in response to a meal ingestion. It is also an important hormone for energy bal- ance regulation (11). Vitamin D deficiency has a negative impact on the level of amylin (12). Many clinical trials have been devoted to finding innovative methods for preventing and treating diabetes mellitus, and the focus of these trials has recently been on vitamin D supplementation. Mirhosseini et al. (13) found that vitamin D supplementation has a significant positive effect on fasting blood glucose (FBG), HbA1c, and homeostasis mod- el assessment of insulin resistance (HOMA- IR). The results of the studies conducted on both humans and animals have shown that vitamin D status and insulin secretion and resistance are linked because both vitamin D receptor and 1- α-hydroxylase are present in the pancreatic β-cells (14). Based on the literature review, there is a constant associa- tion between increased body mass index and decreased serum vitamin D concentrations (15).
Chronic low-grade inflammation, com- monly observed in obese patients, is cor- related with the development of insulin re- sistance, which aggregates the risk of T2D (16). Recent data have shown that severe vitamin D deficiency is associated with in- creased levels of C-reactive protein (CRP), Tumor Necrosis Factor-alfa (TNF-α), and IL -6 (17).
Regarding the high prevalence of T2D among Kurds as well as the premise that T2D may present alongside vitamin D deficiency, the present investigation was aimed to:
1- Conduct an open-label clinical-ana- lytical study on the effects of improved vi- tamin D status on insulin and amylin secre- tion, insulin resistance, insulin sensitivity, and pancreatic β-cell functions; 2- evaluate the effect of vitamin D supplementation on the level of Amylin in T2D Kurdish patients (because amylin is a potential hormone in energy expenditure and glucose hemostasis, although it has been ignored in recent stud-
ies); and 3- evaluate the effects of vitamin D supplementation on inflammatory mark- ers in patients with both T2D and vitamin D deficiency.
To take ethical considerations into ac- count, necessary approval was obtained from the Ethical Committee of the Hawler Medi- cal University prior to the beginning of the study. Moreover, all of the participants filled out a written informed consent and they were all free to leave the study at any phase. The study was conducted in the Endocrinol- ogy Center located in Sulaymaniyah Gover- norate, Iraq from December 1, 2017, to June 1, 2018. The Clinical Analysis Department of the College of Pharmacy of Hawler Medical University cooperated to conduct the study. Adult type-2 diabetic patients with vitamin D deficiency were enrolled in the present study. They were of both genders and aged 40 and over. The exclusion criteria consisted of having malnutrition, terminal illnesses, coronary artery, kidney or hepatic disease. Furthermore, pregnant and nursing patients with serum C-reactive protein (CRP) ≥6 mg/L were excluded from the study.
The target patients were enrolled in the Endocrinology Center in Sulaymaniyah Gov- ernorate, Iraq. Located in the Northern part of Iraq, Sulaymaniyah is a mountainous gov- ernorate characterized by its cold winters, and less sunlight exposure. Each patient was examined by an endocrinologist and the re- searcher’s team. A total of 87 patients (15 males and 72 females) who met the above- mentioned inclusion and exclusion crite- ria were enrolled for 14 weeks of vitamin D supplementation (5000 IU/day), which was added to their treatment regimens. At the beginning of the intervention, the partici- pants were advised to contact the research staff immediately whenever their body react- ed unexpectedly to the supplements.
3
Before and after supplementation with vitamin D , the patients underwent an an-
thropometric evaluation including height (m), weight (kg), and waist circumference (cm) measurements.
Moreover, the Quetelet’s equation (weight (kg)/height (m) 2) was utilized to calculate the patients’ body mass index (BMI). Then, 12-hour overnight fasting ve- nous blood samples were taken from them. The blood samples were divided into two parts; EDTA test tubes were filled with the first part in order to determine the glycosyl- ated haemoglobin (HbA1c) percentage, and the non-coagulant test tubes were filled with the another part in which the sera were cen- trifuged to be separated (3000 rpm for 15 minutes), and they were kept at -20°C for later measurements within 2 weeks of sam- pling.
Enzymatic reaction was also employed for spectrophotometric measurement of lip- id profile (mg/dL) including total high- and low-density lipoprotein-cholesterol (HDL - c & LDL -c), triglyceride (TG), cholesterol (TC), and fasting serum glucose (FSG). Log of TG/HDL -c was calculated in order to de- termine the atherogenicity. Moreover, the technology of enzyme-linked immunosor- bent assay (ELISA) was utilized to determine fasting serum insulin (mU/L), C-peptide (ng/ml), amylin (pg/ml), IL6, TNF-α, and hs-CRP. Homeostatic model assessment of insulin resistance (HOMA-IR) and Homeo- static model assessment of insulin sensitiv- ity (HOMA-IS) was determined through the following formulas:
This study has some limitations includ- ing that it did not control for other poten- tial confounders such as anti-diabetic oral agents, other pharmacological therapies and nutrition intervention.
The results are expressed as frequen- cies, percentages, and whenever possible as means ± SD. Data were analyzed using independent and paired samples t-tests, chi- squared and simple (rho) correlation tests. The level of statistical significance was con- sidered p<0.05; data analysis was conduct- ed using SPSS version 21.0 software (IBM Corp., Armonk, N.Y., USA) and Microsoft Ex- cel (2007).
The present study was conducted on 87 type-2 diabetic patients with a mean age of
50.5 years. The participants consisted of 72 females and 15 males. Regarding their mari- tal status, all were married except two of them. Only four participants were smokers. Moreover, 44 patients had hypertension, and about 61% of them were living in rural areas (Table I).
After 14 weeks of intervention, vitamin D supplement resulted in a sharp improve- ment in the level of vitamin D, which in turn led to a significant reduction in fasting blood glucose, and HbA1c, by a non-significant decrease in HOMA-IR. It also led to an im- provement in the secretion of fasting serum insulin, and significant improvements were observed in C-peptide and amylin (Table II).
Gender | Age±SD /year | Marital status | Residency | Smoking (No.) | Co-morbidity (hypertension) | |||
(No.) | (No.) | (No.) | (No.) | (No.) | (No.) | (No.) | ||
15(17.24) | 72(82.76) | 50.5±7 | 2(2.3) | 85(97.7) | 34(39.1) | 53(60.9) | 4(4.6) | 44(50.5) |
The results are expressed as number (percentage) and mean±SD. |
PATIENTS’ DEMOGRAPHICS.
Male
Female
Single
Married
Urban
Rural
ASSESSMENT OF GLYCAEMIC STATUS AND RELATED BIOMARKERS.
Biomarkers | Before supplementation | After supplementation | P value |
Vitamin D (ng/mL) | 13.5 ± 6.34 | 33.21 ± 10.14 | <0.001 |
Fasting serum glucose (mg/dL) | 219.8 ± 64.4 | 176.6 ± 55.9 | |
Glycated hemoglobin (HbA1c%) | 9.9 ± 1.52 | 8.44 ± 1.45 | |
Amylin (pg/mL) | 388.0 ± 279.6 | 426.0 ± 309.1 | |
Fasting serum insulin (µ unit/mL) | 14.2 ± 10.05 | 16.56 ± 10.08 | |
HOMA-IR | 8.0 ± 7.36 | 6.96 ± 4 | 0.125 |
HOMA-IS | 0.125 ± 5.6 | 0.144 ± 3.5 | 0.09 |
C-peptide (ng/mL) | 2.3 ± 0.76 | 2.97 ± 0.9 | 0.036 |
The results are expressed as mean±SD. P-value represents the level of significant difference between pre-and post- treatment using two-tailed paired t-test. HOMA-IR: Homeostatic model assessment for insulin resistance. HOMA-IS: Homeostatic model assessment of insulin sensitivity. |
Furthermore, after 14 weeks of the 5000 IU/day vitamin D supplementation, the chronic low-grade inflammatory mark- ers (high sensitivity C-reactive protein, in- terleukin 6, and tumor necrosis factor-α) decreased significantly (Table III).
Waist circumference (WC) and Body Mass Index (BMI) decreased significantly af-
ter 14 weeks of vitamin D supplementation. Triglycerides, triglyceride to high-density li- poprotein ratio, and HDL also increased sig- nificantly. However, total cholesterol and LDL decreased after supplementation, but these differences were not significant (Table IV).
Biomarkers | Before supplementation | After supplementation | p-value |
High sensitivity C-reactive protein (mg/L) Interleukin 6 (ng/mL) Tumor necrosis factor-α (ng/mL) | 3.04 ± 1.68 198.3 ± 84.8 187.4 ± 94.7 | 2.53 ± 1.42 176.2 ± 79.6 169.3 ± 95.2 | |
ASSESSMENT OF INFLAMMATORY MARKERS AND RELATED BIOMARKERS
<0.001
The results are expressed as mean±SD. P value represents the level of significant difference between pre-and post- treatment using two-tailed paired t-test.
Determinates | Before supplementation | After supplementation | P-value |
Waist circumference (cm) Body mass index (kg/m2) High-density lipoprotein-cholesterol (mg/dL) Triglyceride to high-density lipoprotein ratio Total cholesterol mg/dL) Triglyceride (mg/dL) Low density lipoprotein-cholesterol (mg/dL) | 100 ± 6.5 25.7 ± 2.9 38.1 ± 11.8 4.6 ± 3.288 178.5 ± 40 154.8 ± 69.6 117.6 ± 31.5 | 98.5 ± 6.6 25.4 ± 2.9 42.5 ± 10.6 3.7 ± 2.371 176.8 ± 37.5 143.4 ± 65.2 114.6 ± 30.5 | |
0.534 | |||
0.019 | |||
0.278 | |||
The results are expressed as mean±SD. P value represents the level of significant difference between pre-and post- treatment using two-tailed paired t-test. |
ANTHROPOMETRIC MEASUREMENTS AND FASTING LIPID PROFILE DATA
<0.001
Considered as a global problem, vita- min D deficiency is observed in both tropi- cal countries and those with temperate cli- mate (18). Furthermore, vitamin D plays an important role in bone homeostasis. Data from observational studies have shown an association between vitamin D deficiency and chronic disorders such as diabetes, autoimmune and cardiovascular diseases (19). Type-2 diabetes is one of the leading non-communicable chronic diseases whose complications have become major causes of morbidity and mortality worldwide (1). It has also been indicated by observational studies, that there is an association between vitamin D deficiency and the onset and pro- gression of T2D, as well as future macro- vascular events (5-9). While, a randomized, double blind, placebo-controlled clinical tri- al among persons at high risk for T2D, found that vitamin D3 supplementation did not re- sult in a significantly lower risk of diabetes than placebo (20).
In the present study, all of the patients had T2D and suffered from vitamin D defi- ciency. The effects of vitamin D supplement on glycemic status and chronic low-grade in- flammatory markers in T2D were evaluated in this study. Vitamin D supplementation for 14 weeks considerably affected glycemic indices, insulin resistance, and systemic in- flammation.
Findings of the present study demon- strated that vitamin D (5000 IU/day) sup- plementation resulted in a significant drop in the percentage of HbA1c and the level of fasting blood glucose, but it increased secre- tion of amylin and C-peptide remarkably and insulin non-significantly from pancreatic β-cells. Furthermore, the improved vitamin D level after supplementation (5000 IU/day) resulted in decreased HOMA-IR, which indi- cates the improvement in insulin sensitivity and decreased insulin resistance. Refined vi- tamin D status negatively affected the mark- ers of inflammation through dropping the
circulatory levels of IL6, TNF-α, and hs-CRP. These results are along the lines of other re- lated studies in which vitamin D supplemen- tation improves insulin sensitivity (21) and reduces systemic inflammation(22).
Other study showed that supplementa- tion with vitamin D for 12 weeks, compared with the placebo in patients with DFU, led to a significant reduction in HOMA-IR and HbA1c (23). Moreover, one-year 420 IU/day vitamin D supplementation increased serum 25(OH) D concentration, resulting in ben- eficial effects on fasting glucose level and in- sulin resistance (24). However, supplemen- tation with 1000 IU/day vitamin D among healthy overweight women for 12 weeks did not affect the insulin resistance (25).
In terms of inflammation, vitamin D supplementation reduced hs-CRP, IL -6, and TNF-α significantly, and this finding is con- sistent with other studies (23, 26-29). Ma- tias et al. (30) also observed a significant reduction in the serum hs-CRP level at the one-year follow-up of patients with vitamin D deficiency who received high doses of vi- tamin D3. Although in a study conducted on patients with major depressive disorder, it was found that taking 50,000 IU/week vi- tamin D supplemention for 8 weeks did not affect hs-CRP level (31).
Witham et al. (32) found no reduction in the hs-CRP level after 8 weeks of supple- mentation with a single dose of 100,000 IU vitamin D3 in women in southern Asia. Pit- tas et al. (33) also found no reduction in the CRP, interleukin 6 (IL -6), and tumor necro- sis factor-α (TNF-α) levels. Favorable effects of vitamin D intake on markers of insulin re- sistance can be explained through its impact on calcium and phosphorus metabolism as well as up-regulation of the insulin receptor gene and increased transcription of insulin receptor genes (34).
One of the strengths of the present study is the assessment of serum biomarkers related to β-cells function such as c-peptide, amylin and 25(OH)D. C-peptide secreted in equimolar concentration to insulin is widely
considered as a better marker of residual β-cells function than insulin due to its lon- ger half-life (35). In addition to C-peptide, amylin, as mentioned before, is a glucoregu- latory hormone co-secreted with insulin in response to food intake to complement insu- lin dependent maintenance of postprandial glucose homeostasis (12). Interestingly, pos- itive associations of insulin, C-peptide, and amylin with 25(OH) D were identified in the results of the present study.
Vitamin D supplementation (5000 IU daily) for 14 weeks led to a significant de- crease in FBS and HbA1c by increasing the synthesis of amylin, insulin, and c-peptide. Furthermore, insulin resistance decreased, while insulin sensitivity increased as a result of the significant reduction in IL6 and TNF-α.
014-0081-9.
1428.
6156.1000213.
Talaei A, Mohamadi M, Adgi Z. The effect of vitamin D on insulin resistance in pa- tients with type 2 diabetes. Diabetol Metab Syndr 2013;26;5(1):8. doi: 10.1186/1758- 5996-5-8.
Sepehrmanesh Z, Kolahdooz F, Abedi F, Mazroii N, Assarian A, Asemi Z, Esmaillza- deh A. Vitamin D supplementation affects the Beck depression inventory, insulin re- sistance, and biomarkers of oxidative stress in patients with major depressive disorder: A randomized, controlled clinical trial. J Nutr 2016;146(2):243-248. doi: 10.3945/ jn.115.218883. Epub 2015 Nov 25.